สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

lannett company, inc. - levorphanol tartrate (unii: 04wqu6t9qi) (levorphanol - unii:27618j1n2x) - levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see warnings] , reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia levorphanol tartrate tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. levorphanol tartrate tablets are contraindicated in patients with: - significant respiratory depression [see warnings] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings]  - hypersensitivity to levorphanol or any of the formulation excipients (e.g., anaphylaxis) [see warnings] levorphanol tartrate tablets contains levorphanol, a schedule ii controlled substance. levorphanol tartrate tablets contains levorphanol, a substance with high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see warnings]. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. misuse and abuse of levorphanol tartrate tablets increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. the risk is increased with concurrent abuse of levorphanol tartrate tablets with alcohol and other cns depressants. abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. in addition, abuse of opioids can occur in the absence of addiction. all patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. patients at high risk of levorphanol tartrate tablets abuse include those with a history of prolonged use of any opioid, including products containing levorphanol, those with a history of drug or alcohol abuse, or those who use levorphanol tartrate tablets in combination with other abused drugs. “drug-seeking” behavior is very common in persons with substance use disorders. drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control. levorphanol tartrate tablets, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. risks specific to abuse of levorphanol tartrate tablets abuse of levorphanol tartrate tablets poses a risk of overdose and death. the risk is increased with concurrent use of levorphanol tartrate tablets with alcohol and/or other cns depressants. parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and hiv. both tolerance and physical dependence can develop during use of opioid therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use. do not abruptly discontinue levorphanol tartrate tablets in a patient physically dependent on opioids. rapid tapering of levorphanol tartrate tablets in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. when discontinuing levorphanol tartrate tablets, gradually taper the dosage using a patient- specific plan that considers the following: the dose of levorphanol tartrate tablets the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. to improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. in patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see dosage and administration, and warnings] . infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see pregnancy] .

สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

lannett company, inc. - doxepin hydrochloride (unii: 3u9a0fe9n5) (doxepin - unii:5asj6huz7d) - doxepin hydrochloride is recommended for the treatment of:     1. psychoneurotic patients with depression and/or anxiety.     2. depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol).     3. depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly).     4. psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. the target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. clinical experience has shown that doxepin hydrochloride is safe and well tolerated even in the elderly patient. owing to lack of clinical experience in the pediatric population, doxepin hydrochloride is not recommended for use in children under 12 year

สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

lannett company, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - attention deficit disorders, narcolepsy attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hcl oral solution is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dy

มอลตา - อังกฤษ - Malta Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

มอลตา - อังกฤษ - Malta Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

best choice (valu merchandisers company) - tetrahydrozoline hydrochloride (unii: 0yzt43hs7d) (tetrahydrozoline - unii:s9u025y077), zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - purposes tetrahydrozoline hcl......redness reliever zinc sulfate......astringent use - for temporary relief of discomfort and redness of the eye due to minor eye irritation

สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

heb grocery company., lp - tetrahydrozoline hydrochloride (unii: 0yzt43hs7d) (tetrahydrozoline - unii:s9u025y077), zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - purposes tetrahydrozoline hcl......redness reliever zinc sulfate......astringent use - for temporary relief of discomfort and redness of the eye due to minor eye irritation

อียิปต์ - อังกฤษ - EDA (Egyptian Drug Authority)

tiba company for pharmaceutical ind. - topical ointment - 20 %

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

sigma company limited - ascorbic acid,echinacea purpurea,lysine hydrochloride,zinc amino acid chelate -

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

sigma company limited - zinc oxide, quantity: 9.336 mg (equivalent: zinc, qty 7.5 mg); ferrous fumarate, quantity: 15.211 mg (equivalent: iron, qty 5 mg); nicotinamide, quantity: 15 mg; calcium pantothenate, quantity: 10.8 mg; colecalciferol, quantity: 15 microgram; ascorbic acid, quantity: 90 mg; pyridoxine hydrochloride, quantity: 6 mg (equivalent: pyridoxine, qty 4.92 mg); biotin, quantity: 45 microgram; cyanocobalamin, quantity: 20 microgram; folic acid, quantity: 300 microgram; betacarotene, quantity: 1.8 mg; dl-alpha-tocopheryl acetate, quantity: 74.5 mg; heavy magnesium oxide, quantity: 82.919 mg (equivalent: magnesium, qty 50 mg); chromic chloride hexahydrate, quantity: 179.3 microgram (equivalent: chromium, qty 35 microgram); potassium iodide, quantity: 196 microgram (equivalent: iodine, qty 150 microgram); calcium carbonate, quantity: 499.5 mg (equivalent: calcium, qty 200 mg); cupric sulfate pentahydrate, quantity: 3.929 mg (equivalent: copper, qty 1 mg); manganese sulfate monohydrate, quantity: 15.38 mg (equivalent: manganese, qty 5 mg); potassium sulfate, quantity: 178.253 mg (equivalent: potassium, qty 80 mg); riboflavin, quantity: 3.2 mg; thiamine nitrate, quantity: 2.689 mg (equivalent: thiamine, qty 2.18 mg); lutein, quantity: 500 microgram; phytomenadione, quantity: 25 microgram; retinol acetate, quantity: 344.1 microgram (equivalent: vitamin a, qty 300 re); lycopene, quantity: 600 microgram; sodium selenate, quantity: 124.8 microgram (equivalent: selenium, qty 52 microgram) - tablet, film coated - excipient ingredients: maize starch; titanium dioxide; butylated hydroxytoluene; dl-alpha-tocopheryl acetate; sodium ascorbate; sucrose; silicon dioxide; purified water; dl-alpha-tocopherol; starch sodium octenyl succinate; hydrolysed maize starch; croscarmellose sodium; microcrystalline cellulose; maize oil; medium chain triglycerides; sunset yellow fcf aluminium lake; macrogol 400; purified talc; magnesium stearate; colloidal anhydrous silica; maltodextrin; potato starch; hypromellose; butylated hydroxyanisole; gelatin - antioxidant/reduce free radicals formed in the body ; maintain/support energy levels ; maintain/support eye health ; maintain/support general health and wellbeing ; maintain/support bone health ; maintain/support immune system health ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency